A5000715339- Amyotrophic Lateral Sclerosis Research
- Parkinson's Disease Mechanisms and Treatments
- Neurogenetic and Muscular Disorders Research
- Genetic Neurodegenerative Diseases
- Dysphagia Assessment and Management
- Respiratory Support and Mechanisms
- Family and Disability Support Research
- Alzheimer's disease research and treatments
- Prion Diseases and Protein Misfolding
- Biochemical Acid Research Studies
- Psychiatric care and mental health services
- Cystic Fibrosis Research Advances
- Voice and Speech Disorders
- Cerebrospinal fluid and hydrocephalus
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Neurological disorders and treatments
King's College London
2015-2025
King's College Hospital
2015-2025
UK Dementia Research Institute
2020
Edinburgh Royal Infirmary
2018
Alzheimer Scotland
2018
Trinity College
2018
Beaumont Hospital
2018
King's College Hospital NHS Foundation Trust
2015
To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS), as measured with King's Clinical Staging System, and cognitive behavioral change, Edinburgh Cognitive Behavioural ALS Screen (ECAS).A large multicenter observational cohort of 161 cross-sectional patients 80 healthy matched controls were recruited across 3 research sites (Dublin, Edinburgh, London). Participants administered ECAS categorized into independent groups based on their clinical at time...
Objective symptom monitoring of patients with Amyotrophic Lateral Sclerosis (ALS) has the potential to provide an important source information evaluate impact disease on aspects real-world functional capacity and activities daily living in home setting, providing useful objective outcome measures for clinical trials.This study aimed investigate feasibility a novel digital platform remote data collection multiple symptoms-physical activity, heart rate variability (HRV), speech...
Objective: Progressing respiratory weakness throughout the course of amyotrophic lateral sclerosis (ALS) is clinically associated with distressing symptoms, including dyspnea, orthopnea, and difficulty clearing secretions. Fatigue, poor sleep, reduced quality life are also considered to be declining function. Respiratory measurements guide prescription interventions, which aim alleviate symptoms. The relationships between patient reported symptoms currently unclear. Method: REVEALS study was...
Motor neuron disease (MND) is a fatal, progressive neurodegenerative that causes weakening and wasting of limb, bulbar, thoracic abdominal muscles. Clear evidence-based guidance on how psychological distress should be managed in people living with MND (plwMND) lacking. Acceptance Commitment Therapy (ACT) form therapy may particularly suitable for this population. However, to the authors' knowledge, no study date has evaluated ACT plwMND. Consequently, primary aim uncontrolled feasibility was...
Objective To systematically assess decline in respiratory measures amyotrophic lateral sclerosis (ALS) and to examine the impact of sex, disease onset type baseline morbidity on progression.
Objective To explore novel, real-world biotelemetry disease progression markers in patients with amyotrophic lateral sclerosis (ALS) and to compare clinical gold-standard measures. Methods: This was an exploratory, non-controlled, non-drug 2-phase study comprising a variable length Pilot Phase (n = 5) 48-week Core 25; NCT02447952). Patients mild or moderate ALS wore sensors for ∼3 days/month at home, measuring physical activity, heart rate variability (HRV), speech over 48 weeks. These...
Background: An ongoing longitudinal study in six European sites includes a 3-monthly assessment of forced vital capacity (FVC), slow (SVC), peak cough flow (PCF), and Sniff nasal inspiratory pressure (SNIP). The aim this interim analysis was to assess the potential for SNIP be surrogate aerosol generating procedures given COVID-19 related restrictions. Methods: This prospective observational study. Patients attending with King's Stage 2 or 3 ALS completed baseline FVC/SVC/SNIP/PCF repeated...
: Amyotrophic lateral sclerosis (ALS) shows considerable clinical heterogeneity, which affects trials. A staging system has been proposed for ALS with potential applications in patient care, research, trial design and health economic analyses. The King's consists of five stages. We have previously shown that progressive stages were reached at predictable proportions through the disease course, but this needs to be validated other independent samples.
<sec> <title>BACKGROUND</title> Objective symptom monitoring of patients with Amyotrophic Lateral Sclerosis (ALS) has the potential to provide an important source information evaluate impact disease on aspects real-world functional capacity and activities daily living in home setting, providing useful objective outcome measures for clinical trials. </sec> <title>OBJECTIVE</title> This study aimed investigate feasibility a novel digital platform remote data collection multiple...